The implementation of the Ontario biosimilars transition policy

In this episode of Arthritis At Home, Cheryl Koehn speaks to Dr. Jane Purvis, an Ontario rheumatologist and the Chair of Government Affairs Committee of the Ontario Rheumatology Association, about the biosimilars transition policy being implemented in Ontario. Dr. Purvis reminds our Ontario inflammatory arthritis patient audience that if they are affected by this policy, they have until December 29, 2023 to make the transition. During this transition period, Dr. Purvis also encourages patients not to wait until the last minute and make an appointment now to discuss what transition means for them, what their treatment options are and how to make a transition plan with their rheumatologist through in-person or virtual visits.Additional learning resourcesOntario Ministry of Health – Biosimilars: Information for PatientsBiosimilars•Exchange: Canada’s trusted source for timely news and information on biosimilar biologicsJointHealthTM education: Biosimilars Education Video Series